Compare SHBI & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHBI | CADL |
|---|---|---|
| Founded | 1876 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 757.4M | 723.9M |
| IPO Year | 1997 | 2021 |
| Metric | SHBI | CADL |
|---|---|---|
| Price | $23.22 | $9.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $19.17 | $19.00 |
| AVG Volume (30 Days) | 217.9K | ★ 2.0M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | 34.85 | ★ 58.62 |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $20,853,000.00 | $125,000.00 |
| Revenue This Year | $8.97 | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | $46.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.93 | $4.35 |
| 52 Week High | $23.68 | $11.36 |
| Indicator | SHBI | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 62.10 | 57.66 |
| Support Level | $21.81 | $4.80 |
| Resistance Level | N/A | $11.36 |
| Average True Range (ATR) | 0.51 | 0.62 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 77.78 | 32.37 |
Shore Bancshares Inc is a financial holding company based in the United States. Through its subsidiaries, it provides consumer and commercial banking products and services, as well as secondary mortgage lending, trust, wealth management, and financial planning services. The group caters to both business and individual clients, offering checking, savings, certificates of deposit, and overnight investment sweep accounts; commercial lending services, including secured and unsecured loans, working capital loans, lines of credit, etc; and safe deposit boxes, debit cards, telephone banking, and other financial products and services.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.